Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 73
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
2.
Nat Immunol ; 10(9): 1026-33, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19668219

RESUMEN

Type 1 diabetes may result from a breakdown in peripheral tolerance that is partially controlled by the expression of peripheral tissue antigens (PTAs) in lymph nodes. Here we show that the transcriptional regulator Deaf1 controls the expression of genes encoding PTAs in the pancreatic lymph nodes (PLNs). The expression of canonical Deaf1 was lower, whereas that of an alternatively spliced variant was higher, during the onset of destructive insulitis in the PLNs of nonobese diabetic (NOD) mice. We identified an equivalent variant Deaf1 isoform in the PLNs of patients with type 1 diabetes. Both the NOD mouse and human Deaf1 variant isoforms suppressed PTA expression by inhibiting the transcriptional activity of canonical Deaf1. Lower PTA expression resulting from the alternative splicing of DEAF1 may contribute to the pathogenesis of type 1 diabetes.


Asunto(s)
Antígenos/genética , Diabetes Mellitus Tipo 1/inmunología , Ganglios Linfáticos/inmunología , Proteínas Nucleares/fisiología , Páncreas/inmunología , Empalme Alternativo , Animales , Secuencia de Bases , Proteínas de Unión al ADN , Femenino , Regulación de la Expresión Génica , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NOD , Datos de Secuencia Molecular , Isoformas de Proteínas , Factores de Transcripción
3.
Proc Natl Acad Sci U S A ; 115(27): 7081-7086, 2018 07 03.
Artículo en Inglés | MEDLINE | ID: mdl-29915045

RESUMEN

Although certain dogma portrays amyloid fibrils as drivers of neurodegenerative disease and neuroinflammation, we have found, paradoxically, that amyloid fibrils and small heat shock proteins (sHsps) are therapeutic in experimental autoimmune encephalomyelitis (EAE). They reduce clinical paralysis and induce immunosuppressive pathways, diminishing inflammation. A key question was the identification of the target for these molecules. When sHsps and amyloid fibrils were chemically cross-linked to immune cells, a limited number of proteins were precipitated, including the α7 nicotinic acetylcholine receptor (α7 NAChR). The α7 NAChR is noteworthy among the over 20 known receptors for amyloid fibrils, because it plays a central role in a well-defined immune-suppressive pathway. Competitive binding between amyloid fibrils and α-bungarotoxin to peritoneal macrophages (MΦs) confirmed the involvement of α7 NAChR. The mechanism of immune suppression was explored, and, similar to nicotine, amyloid fibrils inhibited LPS induction of a common set of inflammatory cytokines while inducing Stat3 signaling and autophagy. Consistent with this, previous studies have established that nicotine, sHsps, and amyloid fibrils all were effective therapeutics in EAE. Interestingly, B lymphocytes were needed for the therapeutic effect. These results suggest that agonists of α7 NAChR might have therapeutic benefit for a variety of inflammatory diseases.


Asunto(s)
Amiloide/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Proteínas de Choque Térmico/inmunología , Macrófagos Peritoneales/inmunología , Nicotina/inmunología , Receptor Nicotínico de Acetilcolina alfa 7/inmunología , Animales , Linfocitos B/inmunología , Linfocitos B/patología , Encefalomielitis Autoinmune Experimental/patología , Humanos , Tolerancia Inmunológica , Macrófagos Peritoneales/patología , Ratones
4.
Nature ; 484(7395): 529-33, 2012 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-22446627

RESUMEN

The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of leukocytes, including T cells and natural killer (NK) cells. Considerable effort has been invested in using IL-2 as a therapeutic agent for a variety of immune disorders ranging from AIDS to cancer. However, adverse effects have limited its use in the clinic. On activated T cells, IL-2 signals through a quaternary 'high affinity' receptor complex consisting of IL-2, IL-2Rα (termed CD25), IL-2Rß and IL-2Rγ. Naive T cells express only a low density of IL-2Rß and IL-2Rγ, and are therefore relatively insensitive to IL-2, but acquire sensitivity after CD25 expression, which captures the cytokine and presents it to IL-2Rß and IL-2Rγ. Here, using in vitro evolution, we eliminated the functional requirement of IL-2 for CD25 expression by engineering an IL-2 'superkine' (also called super-2) with increased binding affinity for IL-2Rß. Crystal structures of the IL-2 superkine in free and receptor-bound forms showed that the evolved mutations are principally in the core of the cytokine, and molecular dynamics simulations indicated that the evolved mutations stabilized IL-2, reducing the flexibility of a helix in the IL-2Rß binding site, into an optimized receptor-binding conformation resembling that when bound to CD25. The evolved mutations in the IL-2 superkine recapitulated the functional role of CD25 by eliciting potent phosphorylation of STAT5 and vigorous proliferation of T cells irrespective of CD25 expression. Compared to IL-2, the IL-2 superkine induced superior expansion of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionally less expansion of T regulatory cells and reduced pulmonary oedema. Collectively, we show that in vitro evolution has mimicked the functional role of CD25 in enhancing IL-2 potency and regulating target cell specificity, which has implications for immunotherapy.


Asunto(s)
Evolución Molecular Dirigida , Interleucina-2/química , Interleucina-2/inmunología , Proteínas Mutantes/química , Proteínas Mutantes/inmunología , Ingeniería de Proteínas , Animales , Sitios de Unión , Línea Celular , Proliferación Celular , Cristalografía por Rayos X , Humanos , Inmunoterapia , Interleucina-2/genética , Interleucina-2/farmacología , Subunidad alfa del Receptor de Interleucina-2/química , Subunidad alfa del Receptor de Interleucina-2/deficiencia , Subunidad alfa del Receptor de Interleucina-2/inmunología , Subunidad alfa del Receptor de Interleucina-2/metabolismo , Subunidad beta del Receptor de Interleucina-2/química , Subunidad beta del Receptor de Interleucina-2/metabolismo , Células Asesinas Naturales/inmunología , Ratones , Ratones Endogámicos C57BL , Modelos Moleculares , Simulación de Dinámica Molecular , Proteínas Mutantes/genética , Proteínas Mutantes/farmacología , Mutación , Trasplante de Neoplasias , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Fosforilación , Conformación Proteica , Factor de Transcripción STAT5/metabolismo , Resonancia por Plasmón de Superficie , Linfocitos T/citología , Linfocitos T/inmunología
5.
Proc Natl Acad Sci U S A ; 112(49): 15016-23, 2015 Dec 08.
Artículo en Inglés | MEDLINE | ID: mdl-26621719

RESUMEN

Amyloid fibrils composed of peptides as short as six amino acids are therapeutic in experimental autoimmune encephalomyelitis (EAE), reducing paralysis and inflammation, while inducing several pathways of immune suppression. Intraperitoneal injection of fibrils selectively activates B-1a lymphocytes and two populations of resident macrophages (MΦs), increasing IL-10 production, and triggering their exodus from the peritoneum. The importance of IL-10-producing B-1a cells in this effective therapy was established in loss-of-function experiments where neither B-cell-deficient (µMT) nor IL10(-/-) mice with EAE responded to the fibrils. In gain-of-function experiments, B-1a cells, adoptively transferred to µMT mice with EAE, restored their therapeutic efficacy when Amylin 28-33 was administered. Stimulation of adoptively transferred bioluminescent MΦs and B-1a cells by amyloid fibrils resulted in rapid (within 60 min of injection) trafficking of both cell types to draining lymph nodes. Analysis of gene expression indicated that the fibrils activated the CD40/B-cell receptor pathway in B-1a cells and induced a set of immune-suppressive cell-surface proteins, including BTLA, IRF4, and Siglec G. Collectively, these data indicate that the fibrils activate B-1a cells and F4/80(+) MΦs, resulting in their migration to the lymph nodes, where IL-10 and cell-surface receptors associated with immune-suppression limit antigen presentation and T-cell activation. These mechanisms culminate in reduction of paralytic signs of EAE.


Asunto(s)
Amiloide/farmacología , Linfocitos B/inmunología , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Activación de Linfocitos/efectos de los fármacos , Traslado Adoptivo , Amiloide/metabolismo , Amiloide/uso terapéutico , Animales , Encefalomielitis Autoinmune Experimental/inmunología , Endocitosis , Femenino , Interleucina-10/fisiología , Polipéptido Amiloide de los Islotes Pancreáticos/farmacología , Ratones , Ratones Endogámicos C57BL
6.
Nat Rev Immunol ; 7(8): 599-609, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17612584

RESUMEN

Directing both innate and adaptive immune responses against foreign pathogens with correct timing, location and specificity is a fundamental objective for the immune system. Full activation of CD4+ T cells requires the binding of peptide-MHC complexes coupled with accessory signals provided by the antigen-presenting cell. However, aberrant activation of the T-cell receptor alone in mature T cells can produce a long-lived state of functional unresponsiveness, known as anergy. Recent studies probing both immune signalling pathways and the ubiquitin-proteasome system have helped to refine and elaborate current models for the molecular mechanisms underlying T-cell anergy. Controlling anergy induction and maintenance will be a key component in the future to mitigate unwanted T-cell activation that leads to autoimmune disease.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Anergia Clonal/inmunología , Animales , Humanos , Activación de Linfocitos/inmunología , Proteoma/inmunología , Transducción de Señal/inmunología , Ubiquitina-Proteína Ligasas/inmunología
7.
BMC Genomics ; 18(1): 636, 2017 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-28821222

RESUMEN

BACKGROUND: The natural history of type 1 diabetes (T1D) is challenging to investigate, especially as pre-diabetic individuals are difficult to identify. Numerous T1D consortia have been established to collect whole blood for gene expression analysis from individuals with or at risk to develop T1D. However, with no universally accepted protocol for their collection, differences in sample processing may lead to variances in the results. Here, we examined whether the choice of blood collection tube and RNA extraction kit leads to differences in the expression of genes that are changed during the progression of T1D, and if these differences could be minimized by measuring gene expression directly from the lysate of whole blood. RESULTS: Microarray analysis showed that the expression of 901 genes is highly influenced by sample processing using the PAXgene versus the Tempus system. These included a significant number of lymphocyte-specific genes and genes whose expression has been reported to differ in the peripheral blood of at-risk and T1D patients compared to controls. We showed that artificial changes in gene expression occur when control and T1D samples were processed differently. The sample processing-dependent differences in gene expression were largely due to loss of transcripts during the RNA extraction step using the PAXgene system. The majority of differences were not observed when gene expression was measured in whole blood lysates prepared from blood collected in PAXgene and Tempus tubes. CONCLUSION: We showed that the gene expression profile of samples processed using the Tempus system is more accurate than that of samples processed using the PAXgene system. Variation in sample processing can result in misleading changes in gene expression. However, these differences can be minimized by measuring gene expression directly in whole blood lysates.


Asunto(s)
Recolección de Muestras de Sangre/métodos , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/genética , Perfilación de la Expresión Génica/métodos , Leucocitos Mononucleares/metabolismo , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis de Secuencia por Matrices de Oligonucleótidos , Adulto Joven
8.
Stem Cells ; 34(4): 809-19, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26840009

RESUMEN

The evolution of Type 1 diabetes (T1D) therapy has been marked by consecutive shifts, from insulin replacement to immunosuppressive drugs and targeted biologics (following the understanding that T1D is an autoimmune disease), and to more disease-specific or patient-oriented approaches such as antigen-specific and cell-based therapies, with a goal to provide efficacy, safety, and long-term protection. At the same time, another important paradigm shift from treatment of new onset T1D patients to prevention in high-risk individuals has taken place, based on the hypothesis that therapeutic approaches deemed sufficiently safe may show better efficacy if applied early enough to maintain endogenous ß cell function, a concept supported by many preclinical studies. This new strategy has been made possible by capitalizing on a variety of biomarkers that can more reliably estimate the risk and rate of progression of the disease. More advanced ("omic"-based) biomarkers that also shed light on the underlying contributors of disease for each individual will be helpful to guide the choice of the most appropriate therapies, or combinations thereof. In this review, we present current efforts to stratify patients according to biomarkers and current alternatives to conventional drug-based therapies for T1D, with a special emphasis on cell-based therapies, their status in the clinic and potential for treatment and/or prevention.


Asunto(s)
Autoinmunidad , Tratamiento Basado en Trasplante de Células y Tejidos , Diabetes Mellitus Tipo 1/terapia , Células Secretoras de Insulina/patología , Biomarcadores/metabolismo , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/patología , Humanos , Insulina/metabolismo , Células Secretoras de Insulina/trasplante , Trasplante de Células Madre Mesenquimatosas , Linfocitos T/inmunología , Linfocitos T/metabolismo
9.
Nat Chem Biol ; 8(12): 990-8, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23103943

RESUMEN

Cytokines dimerize their receptors, with the binding of the 'second chain' triggering signaling. In the interleukin (IL)-4 and IL-13 system, different cell types express varying numbers of alternative second receptor chains (γc or IL-13Rα1), forming functionally distinct type I or type II complexes. We manipulated the affinity and specificity of second chain recruitment by human IL-4. A type I receptor-selective IL-4 'superkine' with 3,700-fold higher affinity for γc was three- to ten-fold more potent than wild-type IL-4. Conversely, a variant with high affinity for IL-13Rα1 more potently activated cells expressing the type II receptor and induced differentiation of dendritic cells from monocytes, implicating the type II receptor in this process. Superkines showed signaling advantages on cells with lower second chain numbers. Comparative transcriptional analysis reveals that the superkines induce largely redundant gene expression profiles. Variable second chain numbers can be exploited to redirect cytokines toward distinct cell subsets and elicit new actions, potentially improving the selectivity of cytokine therapy.


Asunto(s)
Citocinas/fisiología , Interleucina-4/análogos & derivados , Interleucina-4/farmacología , Linfocitos T CD4-Positivos/metabolismo , Diferenciación Celular/efectos de los fármacos , Línea Celular , Células Dendríticas/efectos de los fármacos , Citometría de Flujo , Perfilación de la Expresión Génica , Humanos , Factores Inmunológicos/farmacología , Interleucina-4/química , Mutación/fisiología , Fenotipo , Fosforilación , Ingeniería de Proteínas , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Interleucina-4/efectos de los fármacos , Factor de Transcripción STAT6/metabolismo , Transducción de Señal/efectos de los fármacos , Relación Estructura-Actividad
10.
Wilderness Environ Med ; 25(2): 160-5, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24631228

RESUMEN

BACKGROUND: Frostbite injury occurs when exposure to cold results in frozen tissue. We recently reported a novel mouse model for frostbite injury to be used in screening potentially therapeutic drugs and other modalities. OBJECTIVE: We used the mouse skin frostbite model to evaluate the effect of poly-l-arginine contained in lotion (PAL) applied topically to involved skin. METHODS: Sixty mice were studied in a randomized, double-blind method. Standardized 2.9-cm-diameter circles were tattooed on the mouse dorsum. Magnets snap frozen in dry ice (-78.5°C) were used to create a frostbite injury on skin within the circle as a continuous 5-minute freeze. Mice were treated with prefreeze placebo, postthaw placebo, combined prefreeze and postthaw placebo, prefreeze with PAL, postthaw with PAL, or combined prefreeze and postthaw with PAL. Appearance, healing rate, tissue loss, and histology were recorded until the wounds were healed. RESULTS: Application of PAL before inducing frostbite injury resulted in decreased tissue loss as compared with other treatment conditions. CONCLUSIONS: Applying PAL topically to frostbitten mouse skin caused decreased tissue loss. Poly-l-arginine should be studied further to determine whether it is a beneficial therapeutic modality for frostbite injury.


Asunto(s)
Congelación de Extremidades/tratamiento farmacológico , Péptidos/administración & dosificación , Animales , Modelos Animales de Enfermedad , Congelación de Extremidades/patología , Masculino , Ratones Endogámicos C57BL , Péptidos/farmacología , Cicatrización de Heridas/efectos de los fármacos
11.
J Biol Chem ; 287(13): 9708-9721, 2012 Mar 23.
Artículo en Inglés | MEDLINE | ID: mdl-22308023

RESUMEN

The therapeutic benefit of the small heat shock protein αB-crystallin (HspB5) in animal models of multiple sclerosis and ischemia is proposed to arise from its increased capacity to bind proinflammatory proteins at the elevated temperatures within inflammatory foci. By mass spectral analysis, a common set of ∼70 ligands was precipitated by HspB5 from plasma from patients with multiple sclerosis, rheumatoid arthritis, and amyloidosis and mice with experimental allergic encephalomyelitis. These proteins were distinguished from other precipitated molecules because they were enriched in the precipitate as compared with their plasma concentrations, and they exhibited temperature-dependent binding. More than half of these ligands were acute phase proteins or members of the complement or coagulation cascades. Consistent with this proposal, plasma levels of HspB5 were increased in patients with multiple sclerosis as compared with normal individuals. The combination of the thermal sensitivity of the HspB5 combined with the high local concentration of these ligands at the site of inflammation is proposed to explain the paradox of how a protein believed to exhibit nonspecific binding can bind with some relative apparent selectivity to proinflammatory proteins and thereby modulate inflammation.


Asunto(s)
Proteínas Sanguíneas/inmunología , Chaperonas Moleculares/farmacología , Esclerosis Múltiple/sangre , Cadena B de alfa-Cristalina/farmacología , Amiloidosis/sangre , Amiloidosis/tratamiento farmacológico , Animales , Artritis Reumatoide/sangre , Artritis Reumatoide/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental , Femenino , Humanos , Inflamación/sangre , Inflamación/tratamiento farmacológico , Ratones , Ratones Endogámicos BALB C , Chaperonas Moleculares/sangre , Esclerosis Múltiple/tratamiento farmacológico , Unión Proteica , Cadena B de alfa-Cristalina/sangre
12.
Clin Immunol ; 142(2): 127-38, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22075384

RESUMEN

The signaling pathways utilized by naïve and experienced effector CD4 T cells during activation and proliferation were evaluated. While inhibition of either mTOR or MAPK alone was able to inhibit naïve T cell proliferation, both mTOR and MAPK (ERK) pathway inhibition was required to efficiently block experienced, effector CD4 T cell proliferation. This was demonstrated both in vitro, and in vivo by treating mice with collagen-induced arthritis using mTOR and/or ERK inhibitors. The combination of mTOR and ERK inhibition prevented or treated disease more efficiently than either agent alone. These data illustrate the different requirements of naïve and experienced effector CD4 T cells in the use of the mTOR and MAPK pathways in proliferation, and suggest that therapies targeting both the mTOR and MAPK pathways may be more effective than targeting either pathway alone in the treatment of CD4 T cell-mediated autoimmunity.


Asunto(s)
Artritis Experimental/terapia , Proliferación Celular/efectos de los fármacos , Sistema de Señalización de MAP Quinasas , Linfocitos T Colaboradores-Inductores , Serina-Treonina Quinasas TOR , Animales , Artritis Experimental/inmunología , Benzamidas/farmacología , Benzopiranos/farmacología , Cromonas/farmacología , Difenilamina/análogos & derivados , Difenilamina/farmacología , Quimioterapia Combinada , Femenino , Humanos , Activación de Linfocitos/inmunología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/inmunología , Ratones , Ratones Endogámicos BALB C , Monosacáridos/farmacología , Morfolinas/farmacología , Sirolimus/farmacología , Linfocitos T Colaboradores-Inductores/inmunología , Linfocitos T Colaboradores-Inductores/metabolismo , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Serina-Treonina Quinasas TOR/inmunología
14.
Diabetes ; 71(7): 1490-1507, 2022 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-35499603

RESUMEN

Multiple pathways contribute to the pathophysiological development of type 1 diabetes (T1D); however, the exact mechanisms involved are unclear. We performed differential gene expression analysis in pancreatic islets of NOD mice versus age-matched congenic NOD.B10 controls to identify genes that may contribute to disease pathogenesis. Novel genes related to extracellular matrix development and glucagon and insulin signaling/secretion were changed in NOD mice during early inflammation. During "respective" insulitis, the expression of genes encoding multiple chemosensory olfactory receptors were upregulated, and during "destructive" insulitis, the expression of genes involved in antimicrobial defense and iron homeostasis were downregulated. Islet inflammation reduced the expression of Hamp that encodes hepcidin. Hepcidin is expressed in ß-cells and serves as the key regulator of iron homeostasis. We showed that Hamp and hepcidin levels were lower, while iron levels were higher in the pancreas of 12-week-old NOD versus NOD.B10 mice, suggesting that a loss of iron homeostasis may occur in the islets during the onset of "destructive" insulitis. Interestingly, we showed that the severity of NOD disease correlates with dietary iron intake. NOD mice maintained on low-iron diets had a lower incidence of hyperglycemia, while those maintained on high-iron diets had an earlier onset and higher incidence of disease, suggesting that high iron exposure combined with a loss of pancreatic iron homeostasis may exacerbate NOD disease. This mechanism may explain the link seen between high iron exposure and the increased risk for T1D in humans.


Asunto(s)
Diabetes Mellitus Tipo 1 , Islotes Pancreáticos , Animales , Diabetes Mellitus Tipo 1/metabolismo , Hepcidinas/genética , Hepcidinas/metabolismo , Homeostasis/genética , Inflamación/metabolismo , Hierro/metabolismo , Islotes Pancreáticos/metabolismo , Ratones , Ratones Endogámicos NOD , Páncreas/metabolismo
15.
Front Immunol ; 13: 1046631, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36569931

RESUMEN

Regulatory T cells (Tregs) normally maintain self-tolerance. Tregs recognize "self" such that when they are not working properly, such as in autoimmunity, the immune system can attack and destroy one's own tissues. Current therapies for autoimmunity rely on relatively ineffective and too often toxic therapies to "treat" the destructive inflammation. Restoring defective endogenous immune regulation (self-tolerance) would represent a paradigm shift in the therapy of these diseases. One recent approach to restore self-tolerance is to use "low dose IL-2" as a therapy to increase the number of circulating Tregs. However, studies to-date have not demonstrated that low-dose IL-2 therapy can restore concomitant Treg function, and phase 2 studies in low dose IL-2 treated patients with autoimmune diseases have failed to demonstrate significant clinical benefit. We hypothesize that the defect in self-tolerance seen in autoimmunity is not due to an insufficient number of available Tregs, but rather, due to defects in second messengers downstream of the IL-2R that normally control Treg function and stability. Previous studies from our lab and others have demonstrated that GRAIL (a ubiquitin E3 ligase) is important in Treg function. GRAIL expression is markedly diminished in Tregs from patients with autoimmune diseases and allergic asthma and is also diminished in Tregs of mice that are considered autoimmune prone. In the relevant pathway in Tregs, GRAIL normally blocks cullin ring ligase activity, which inhibits IL-2R desensitization in Tregs and consequently promotes Treg function. As a result of this defect in GRAIL expression, the Tregs of patients with autoimmune diseases and allergic asthma degrade IL-2R-associated pJAK1 following activation with low dose IL-2, and thus cannot maintain pSTAT5 expression. pSTAT5 controls the transcription of genes required for Treg function. Additionally, the GRAIL-mediated defect may also allow the degradation of the mTOR inhibitor, DEP domain-containing mTOR interacting protein (Deptor). This can lead to IL-2R activation of mTOR and loss of Treg stability in autoimmune patients. Using a monoclonal antibody to the remnant di-glycine tag on ubiquitinated proteins after trypsin digestion, we identified a protein that was ubiquitinated by GRAIL that is important in Treg function, cullin5. Our data demonstrate that GRAIL acts a negative regulator of IL-2R desensitization by ubiquitinating a lysine on cullin5 that must be neddylated to allow cullin5 cullin ring ligase activity. We hypothesize that a neddylation inhibitor in combination with low dose IL-2 activation could be used to substitute for GRAIL and restore Treg function and stability in the Tregs of autoimmune and allergic asthma patients. However, the neddylation activating enzyme inhibitors (NAEi) are toxic when given systemically. By generating a protein drug conjugate (PDC) consisting of a NAEi bound, via cleavable linkers, to a fusion protein of murine IL-2 (to target the drug to Tregs), we were able to use 1000-fold less of the neddylation inhibitor drug than the amount required for therapeutically effective systemic delivery. The PDC was effective in blocking the onset or the progression of disease in several mouse models of autoimmunity (type 1 diabetes, systemic lupus erythematosus, and multiple sclerosis) and a mouse model of allergic asthma in the absence of detectable toxicity. This PDC strategy represents targeted drug delivery at its best where the defect causing the disease was identified, a drug was designed and developed to correct the defect, and the drug was targeted and delivered only to cells that needed it, maximizing safety and efficacy.


Asunto(s)
Enfermedades Autoinmunes , Linfocitos T Reguladores , Ratones , Animales , Interleucina-2/metabolismo , Proteínas Cullin/metabolismo , Receptores de Interleucina-2 , Enfermedades Autoinmunes/metabolismo , Serina-Treonina Quinasas TOR/metabolismo
16.
Blood ; 113(26): 6638-47, 2009 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-19363220

RESUMEN

Because of their potent immunoregulatory capacity, dendritic cells (DCs) have been exploited as therapeutic tools to boost immune responses against tumors or pathogens, or dampen autoimmune or allergic responses. Murine bone marrow-derived DCs (BM-DCs) are the closest known equivalent of the blood monocyte-derived DCs that have been used for human therapy. Current imaging methods have proven unable to properly address the migration of injected DCs to small and deep tissues in mice and humans. This study presents the first extensive analysis of BM-DC homing to lymph nodes (and other selected tissues) after intravenous and intraperitoneal inoculation. After intravenous delivery, DCs accumulated in the spleen, and preferentially in the pancreatic and lung-draining lymph nodes. In contrast, DCs injected intraperitoneally were found predominantly in peritoneal lymph nodes (pancreatic in particular), and in omentum-associated lymphoid tissue. This uneven distribution of BM-DCs, independent of the mouse strain and also observed within pancreatic lymph nodes, resulted in the uneven induction of immune response in different lymphoid tissues. These data have important implications for the design of systemic cellular therapy with DCs, and in particular underlie a previously unsuspected potential for specific treatment of diseases such as autoimmune diabetes and pancreatic cancer.


Asunto(s)
Células Dendríticas/citología , Tejido Linfoide/citología , Animales , Células de la Médula Ósea/citología , Movimiento Celular/fisiología , Células Dendríticas/trasplante , Femenino , Genes Reporteros , Inmunoterapia Adoptiva , Inyecciones Intraperitoneales , Inyecciones Intravenosas , Luciferasas de Luciérnaga/análisis , Luciferasas de Luciérnaga/genética , Pulmón , Ganglios Linfáticos/citología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NOD , Ratones Transgénicos , Epiplón , Especificidad de Órganos , Páncreas , Bazo
17.
J Immunol ; 183(1): 438-44, 2009 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-19542455

RESUMEN

Ubiquitination of eukaryotic proteins regulates a broad range of cellular processes, including T cell activation and tolerance. We have previously demonstrated that GRAIL (gene related to anergy in lymphocytes), a transmembrane RING finger ubiquitin E3 ligase, initially described as induced during the induction of CD4 T cell anergy, is also expressed in resting CD4 T cells. In this study, we show that GRAIL can down-modulate the expression of CD83 (previously described as a cell surface marker for mature dendritic cells) on CD4 T cells. GRAIL-mediated down-modulation of CD83 is dependent on an intact GRAIL extracellular protease-associated domain and an enzymatically active cytosolic RING domain, and proceeds via the ubiquitin-dependent 26S proteosome pathway. Ubiquitin modification of lysine residues K168 and K183, but not K192, in the cytoplasmic domain of CD83 was shown to be necessary for GRAIL-mediated degradation of CD83. Reduced CD83 surface expression levels were seen both on anergized CD4 T cells and following GRAIL expression by retroviral transduction, whereas GRAIL knock-down by RNA interference in CD4 T cells resulted in elevated CD83 levels. Furthermore, CD83 expression on CD4 T cells contributes to T cell activation as a costimulatory molecule. This study supports the novel mechanism of ubiquitination by GRAIL, identifies CD83 as a substrate of GRAIL, and ascribes a role for CD83 in CD4 T cell activation.


Asunto(s)
Antígenos CD/metabolismo , Linfocitos T CD4-Positivos/enzimología , Linfocitos T CD4-Positivos/inmunología , Inmunoglobulinas/metabolismo , Glicoproteínas de Membrana/antagonistas & inhibidores , Glicoproteínas de Membrana/metabolismo , Proteínas de la Membrana/fisiología , Ubiquitina-Proteína Ligasas/fisiología , Secuencia de Aminoácidos , Animales , Antígenos CD/biosíntesis , Antígenos CD/genética , Linfocitos T CD4-Positivos/metabolismo , Línea Celular , Anergia Clonal/inmunología , Regulación hacia Abajo/inmunología , Herpesvirus Humano 1/inmunología , Humanos , Proteínas Inmediatas-Precoces/fisiología , Inmunoglobulinas/biosíntesis , Inmunoglobulinas/genética , Activación de Linfocitos/inmunología , Glicoproteínas de Membrana/biosíntesis , Glicoproteínas de Membrana/genética , Proteínas de la Membrana/deficiencia , Proteínas de la Membrana/genética , Ratones , Datos de Secuencia Molecular , Péptido Hidrolasas/metabolismo , Dominios RING Finger/inmunología , Especificidad por Sustrato/inmunología , Ubiquitina-Proteína Ligasas/deficiencia , Ubiquitina-Proteína Ligasas/genética , Antígeno CD83
18.
J Immunol ; 182(10): 5919-28, 2009 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-19414743

RESUMEN

In this study, we demonstrate that the E3 ubiquitin ligase gene related to anergy in lymphocytes (GRAIL) is expressed in quiescent naive mouse and human CD4 T cells and has a functional role in inhibiting naive T cell proliferation. Following TCR engagement, CD28 costimulation results in the expression of IL-2 whose signaling through its receptor activates the Akt-mammalian target of rapamycin (mTOR) pathway. Activation of mTOR allows selective mRNA translation, including the epistatic regulator of GRAIL, Otubain-1 (Otub1), whose expression results in the degradation of GRAIL and allows T cell proliferation. The activation of mTOR appears to be the critical component of IL-2R signaling regulating GRAIL expression. CTLA4-Ig treatment blocks CD28 costimulation and resultant IL-2 expression, whereas rapamycin and anti-IL-2 treatment block mTOR activation downstream of IL-2R signaling. Thus, all three of these biotherapeutics inhibit mTOR-dependent translation of mRNA transcripts, resulting in blockade of Otub1 expression, maintenance of GRAIL, and inhibition of CD4 T cell proliferation. These observations provide a mechanistic pathway sequentially linking CD28 costimulation, IL-2R signaling, and mTOR activation as important requirements for naive CD4 T cell proliferation through the regulation of Otub1 and GRAIL expression. Our findings also extend the role of GRAIL beyond anergy induction and maintenance, suggesting that endogenous GRAIL regulates general cell cycle and proliferation of primary naive CD4 T cells.


Asunto(s)
Linfocitos T CD4-Positivos/metabolismo , Tolerancia Inmunológica , Activación de Linfocitos/inmunología , Proteínas Quinasas/metabolismo , Transducción de Señal/inmunología , Ubiquitina-Proteína Ligasas/metabolismo , Animales , Western Blotting , Antígenos CD28/inmunología , Antígenos CD28/metabolismo , Linfocitos T CD4-Positivos/inmunología , Proliferación Celular , Cisteína Endopeptidasas/inmunología , Cisteína Endopeptidasas/metabolismo , Enzimas Desubicuitinizantes , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Humanos , Ratones , Análisis de Secuencia por Matrices de Oligonucleótidos , Proteínas Quinasas/inmunología , Receptores de Interleucina-2/inmunología , Receptores de Interleucina-2/metabolismo , Serina-Treonina Quinasas TOR , Ubiquitina-Proteína Ligasas/inmunología
19.
Nat Med ; 10(12): 1390-6, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15558056

RESUMEN

We have developed a multiplexed reverse phase protein (RPP) microarray platform for simultaneous monitoring of site-specific phosphorylation of numerous signaling proteins using nanogram amounts of lysates derived from stimulated living cells. We first show the application of RPP microarrays to the study of signaling kinetics and pathway delineation in Jurkat T lymphocytes. RPP microarrays were used to profile the phosphorylation state of 62 signaling components in Jurkat T cells stimulated through their membrane CD3 and CD28 receptors, identifying a previously unrecognized link between CD3 crosslinking and dephosphorylation of Raf-1 at Ser259. Finally, the potential of this technology to analyze rare primary cell populations is shown in a study of differential STAT protein phosphorylation in interleukin (IL)-2-stimulated CD4(+)CD25(+) regulatory T cells. RPP microarrays, prepared using simple procedures and standard microarray equipment, represent a powerful new tool for the study of signal transduction in both health and disease.


Asunto(s)
Células Jurkat/metabolismo , Análisis por Matrices de Proteínas/métodos , Transducción de Señal/fisiología , Complejo CD3/metabolismo , Reactivos de Enlaces Cruzados/metabolismo , Proteínas de Unión al ADN/metabolismo , Humanos , Células Jurkat/fisiología , Cinética , Proteínas de la Leche/metabolismo , Fosforilación , Proteínas Proto-Oncogénicas c-raf/metabolismo , Factor de Transcripción STAT1 , Factor de Transcripción STAT3 , Factor de Transcripción STAT5 , Linfocitos T/metabolismo , Transactivadores/metabolismo
20.
Nat Med ; 9(9): 1144-50, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12925844

RESUMEN

Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation. Suppression of GVHD with maintenance of GVT activity is a desirable outcome for clinical transplantation. We have previously shown that donor-derived CD4+CD25+ regulatory T cells inhibit lethal GVHD after allogeneic bone marrow transplantation across major histocompatibility complex (MHC) class I and II barriers in mice. Here we demonstrate that in host mice with leukemia and lymphoma, CD4+CD25+ regulatory T cells suppress the early expansion of alloreactive donor T cells, their interleukin-2-receptor (IL-2R) alpha-chain expression and their capacity to induce GVHD without abrogating their GVT effector function, mediated primarily by the perforin lysis pathway. Thus, CD4+CD25+ T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells.


Asunto(s)
Trasplante de Médula Ósea/inmunología , Enfermedad Injerto contra Huésped/prevención & control , Linfocitos T/inmunología , Animales , Trasplante de Médula Ósea/efectos adversos , Trasplante de Médula Ósea/métodos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Supervivencia Celular , Femenino , Enfermedad Injerto contra Huésped/inmunología , Interferón gamma/metabolismo , Subunidad alfa del Receptor de Interleucina-2 , Leucemia/inmunología , Leucemia/patología , Leucemia/terapia , Linfoma/terapia , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Mutantes , Perforina , Proteínas Citotóxicas Formadoras de Poros , Receptores de Interleucina/metabolismo , Receptores de Interleucina-2/metabolismo , Linfocitos T/metabolismo , Trasplante Homólogo/efectos adversos , Trasplante Homólogo/inmunología , Trasplante Homólogo/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA